17561871

Source:http://linkedlifedata.com/resource/pubmed/id/17561871

Download in:

Switch to

Custom View

Named Graph Language Inference

Statements in which the resource exists as a subject.
Predicate	Object
rdf:type	pubmed:Citation
lifeskim:mentions	umls-concept:C0040808, umls-concept:C0043237, umls-concept:C0132326, umls-concept:C0164662, umls-concept:C0209738, umls-concept:C0237401, umls-concept:C0542559, umls-concept:C0597198, umls-concept:C1705493
pubmed:issue	5
pubmed:dateCreated	2007-6-12
pubmed:abstractText	In 2003, the World Health Organization (WHO) and Joint United Nations Programme on HIV/AIDS (UNAIDS) introduced the '3 by 5 Initiative' to treat 3 million individuals by the end of 2005. This study evaluates the time to treatment termination, viral load suppression, and detection of drug resistance among antiretroviral-naïve individuals initiating stavudine/lamivudine/nevirapine (d4T/3TC/NVP) in British Columbia, Canada, to provide a context for future programme planning.
pubmed:language	eng
pubmed:journal	http://linkedlifedata.com/resource/pubmed/journal/100897392
pubmed:citationSubset	IM
pubmed:chemical	http://linkedlifedata.com/resource/pubmed/chemical/Anti-HIV Agents, http://linkedlifedata.com/resource/pubmed/chemical/Lamivudine, http://linkedlifedata.com/resource/pubmed/chemical/Nevirapine, http://linkedlifedata.com/resource/pubmed/chemical/Reverse Transcriptase Inhibitors, http://linkedlifedata.com/resource/pubmed/chemical/Stavudine
pubmed:status	MEDLINE
pubmed:month	Jul
pubmed:issn	1464-2662
pubmed:author	pubmed-author:BrummeC JCJ, pubmed-author:HarriganP RPR, pubmed-author:HoggR SRS, pubmed-author:MontanerJ S GJS, pubmed-author:TamL W YLW, pubmed-author:YipBB
pubmed:issnType	Print
pubmed:volume	8
pubmed:owner	NLM
pubmed:authorsComplete	Y
pubmed:pagination	267-70
pubmed:meshHeading	pubmed-meshheading:17561871-Anti-HIV Agents, pubmed-meshheading:17561871-Antiretroviral Therapy, Highly Active, pubmed-meshheading:17561871-British Columbia, pubmed-meshheading:17561871-CD4 Lymphocyte Count, pubmed-meshheading:17561871-Cohort Studies, pubmed-meshheading:17561871-Drug Resistance, Multiple, Viral, pubmed-meshheading:17561871-HIV Infections, pubmed-meshheading:17561871-HIV-1, pubmed-meshheading:17561871-Humans, pubmed-meshheading:17561871-Lamivudine, pubmed-meshheading:17561871-Nevirapine, pubmed-meshheading:17561871-Proportional Hazards Models, pubmed-meshheading:17561871-Retrospective Studies, pubmed-meshheading:17561871-Reverse Transcriptase Inhibitors, pubmed-meshheading:17561871-Stavudine, pubmed-meshheading:17561871-Viral Load, pubmed-meshheading:17561871-World Health Organization
pubmed:year	2007
pubmed:articleTitle	Performance of a World Health Organization first-line regimen (stavudine/lamivudine/nevirapine) in antiretroviral-naïve individuals in a Western setting.
pubmed:affiliation	British Columbia Centre for Excellence in HIV/AIDS, Vancouver, Canada.
pubmed:publicationType	Journal Article, Research Support, Non-U.S. Gov't